Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

This Stock Is Already Up 58% This Year. Is It a Buy?

Summary by The Motley Fool
Key PointsOne of Moderna's leading drug candidates is proving highly effective in clinical trials.It could help expand Moderna's lineup and boost its financial results. 10 stocks we like better than Moderna › The past few years have been challenging for Moderna (NASDAQ: MRNA) as the biotech has failed to maintain strong revenue growth from its coronavirus vaccine. The company's shares have significantly lagged the market since 2022. However, the…

1 Articles

The Motley FoolThe Motley Fool
Lean Left

This Stock Is Already Up 58% This Year. Is It a Buy?

Key PointsOne of Moderna's leading drug candidates is proving highly effective in clinical trials.It could help expand Moderna's lineup and boost its financial results. 10 stocks we like better than Moderna › The past few years have been challenging for Moderna (NASDAQ: MRNA) as the biotech has failed to maintain strong revenue growth from its coronavirus vaccine. The company's shares have significantly lagged the market since 2022. However, the…

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Thursday, January 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Cambridge, Massachusetts icon

Cambridge, Massachusetts

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal